Mecwins is pleased to announce that China’s National Intellectual Property Administration has granted a new patent for its ground-breaking platform for multiplexed, high-throughput and ultra-sensitive optical detection of plasmonic nanoparticle-labelled biomarkers. The patent, entitled “Biosensor Platform and Method for Simultaneous, Multiplexed, Ultra-Sensitive and High Throughput Optical Detection of Biomarkers” (Patent CN7575167B), marks a significant milestone in the advancement of biosensing technology.
This innovative biosensing platform excels in detecting and quantifying biomarkers with unparalleled sensitivity by capturing and analyzing spatially and spectrally resolved data from the biosensor surface using plasmonic nanoparticles as labels. The enhanced precision and efficiency of this technology enables earlier and more accurate diagnosis, ultimately improving patient outcomes and advancing clinical care.
The successful grant of this patent in China demonstrates Mecwins’ unwavering commitment to innovation and excellence in nanotechnology and biosensing. This achievement not only adds to our intellectual property portfolio, but also reinforces our position as a leading innovator of cutting-edge technological solutions within the biotechnology sector. With this patent, Mecwins now has a portfolio of 21 active patents across three different continents, demonstrating our global reach and continued commitment to technology leadership.
Mecwins is committed to maintaining and expanding its patent portfolio to support ongoing research and development efforts. We are delighted to share the official patent certificate, which symbolizes our continued pursuit of technological excellence and our mission to deliver impactful solutions in the biotechnology landscape.
